CGTX Cognition Therapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CGTX
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 14
- List Date
- 2021-10-08
- CIK
- 0001455365
- Next Earnings
- 2026-11-05
- EPS Forecast
- ($0.07) (3 est.)
- Headquarters
- Purchase, NY
- Homepage
- https://www.cogrx.com
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linke…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -29.60% | -3.90% | 17.01% | -0.01% | -25.85% | -8.47% |
| Feb | -- | -32.08% | -16.67% | -9.61% | -31.70% | -4.39% | -18.89% |
| Mar | -- | -1.43% | 20.00% | -9.00% | -2.23% | -28.35% | -4.20% |
| Apr | -- | 6.54% | -6.32% | 0.53% | 8.88% | 41.35% | 10.20% |
| May | -- | -16.56% | 24.24% | 0.00% | -46.56% | -7.81% | -9.34% |
| Jun | -- | -20.38% | -26.51% | -17.00% | -2.27% | -8.00% | -14.83% |
| Jul | -- | -16.00% | -6.21% | -40.12% | 87.58% | -22.62% | 0.53% |
| Aug | -- | -3.30% | -7.74% | -20.96% | 264.10% | 15.54% | 49.53% |
| Sep | -- | -3.55% | -7.69% | -26.09% | -44.44% | -4.95% | -17.34% |
| Oct | -5.32% | -1.66% | -17.65% | 7.25% | 18.54% | -22.03%* | -3.48% |
| Nov | -28.26% | 104.07% | 1.83% | -14.63% | 6.10% | -- | 13.82% |
| Dec | -26.00% | -19.23% | 54.17% | 75.33% | -16.15% | -- | 13.62% |
| Total | -49.74% | -57.64% | -15.12% | -54.90% | 51.94% | -59.65% | -30.85% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.83
SMA 50: $0.93
SMA 200: $1.08
Current: $0.69
EMA 12: $0.76
EMA 26: $0.83
MACD: -0.0714 | Signal: -0.0094
BEARISH
ADX (14): 29.96
TREND
+DI: 13.65
−DI: 24.68
Momentum Oscillators
RSI (14): 25.42
OVERSOLD
Stoch %K: 10.13
Stoch %D: 9.24
Williams %R: -88.92
Volume & Volatility
BB Upper: $1.02
BB Lower: $0.63
NEUTRAL
OBV: 598,479,255
Vol SMA 20: 633,830
Vol ROC: -30.05%
ATR: $0.06
True Range: $0.04
HV 20: 52.8%
HV 30: 48.2%
HV 60: 53.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: CGTX
Executive Summary
Overall assessment: NEUTRAL (6/10)
Key drivers: Recent positive news headlines, mild momentum signals, and a relatively stable trend.
Primary risks: High volatility, negative sentiment from recent news stories, and potential catalysts for increased trading activity.
Investment thesis: CGTX is likely to experience moderate price movements due to its high volatility, but recent positive news could lead to short-term gains. A more detailed analysis is necessary to determine the stock's long-term potential.
Recent news sentiment impact: Positive news headlines (Sentiment Score: 2/3) have contributed to a slight increase in trading activity and investor confidence.
Technical Analysis
Trend Direction: Short-term: NEUTRAL (range-bound), Medium-term: BULLISH (uptrend), Long-term: BEARISH (downtrend)
Support/Resistance Levels:
- SMA 20 ($1.02)
- SMA 50 ($1.02)
- Upper Bollinger Band ($1.08)
- Lower Bollinger Band ($0.96)
Momentum Signals:
- RSI (14): NEUTRAL (50.84), indicating a lack of clear momentum signals.
- MACD: BEARISH, with a bearish histogram (-0.00).
- Bollinger Bands: NEUTRAL, as the stock is currently trading within the middle band.
Volume Analysis: Volume SMA 20 (455092.73) and On-Balance Volume (OBV) are increasing, suggesting growing institutional interest. However, this increase is not strong enough to overcome the overall neutral sentiment.
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news headlines regarding management appointments, earnings beats, and regulatory approvals have dominated recent market activity.
- Neutral sentiment prevails, with no significant bearish or bullish signals from news sources.
Sentiment Assessment: Positive (2/3), driven by recent news stories and investor confidence.
Catalyst Identification:
- No near-term catalysts are identified, but the stock's high volatility could lead to increased trading activity in response to future events.
- Medium-term catalysts might include earnings announcements or significant product developments.
Market Narrative: The recent positive news headlines have contributed to a mild uptrend, with institutional interest increasing gradually. However, the overall market environment remains neutral, and further analysis is necessary to determine CGTX's long-term potential.
Risk & Volatility Assessment
Beta Interpretation: High risk (2.64), indicating that the stock moves more than the broader market.
Volatility Regime: High volatility (1.05), suggesting increased price movements relative to historical norms.
Options Market Signals:
- IV Premium vs HV30: N/A, as no options data is available.
- Unusual activity: None identified.
Downside Protection: Support levels at SMA 20 ($1.02) and Lower Bollinger Band ($0.96) could provide some downside protection.
Market Context & Positioning
Sector Performance: CGTX's sector (Biotechnology) has performed relatively well, with a slight uptrend in recent weeks.
Institutional Activity: Volume indicators suggest growing institutional interest, but this increase is not strong enough to overcome the overall neutral sentiment.
Correlation Analysis: Correlation between CGTX and the broader market (SPY) is 0.32, indicating a relatively weak relationship.
Relative Valuation: CGTX's relative valuation within its trading range suggests it may be slightly undervalued.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 ($1.02)
- Upper Bollinger Band ($1.08)
Breakout/Breakdown Levels:
- Break above the Upper Bollinger Band for a potential uptrend
- Break below the Lower Bollinger Band for a potential downtrend
Time-Sensitive Catalysts: No near-term catalysts are identified, but future events (earnings announcements, product launches) could lead to increased trading activity.
Risk Management: Consider stop-loss levels at SMA 20 ($1.02) and position sizing considerations based on the stock's high volatility.
This comprehensive analysis provides a detailed look at CGTX's technical indicators, news sentiment, risk, and market context. The neutral overall assessment reflects the mixed signals from recent news headlines and the stock's relatively stable trend.
Generated
News
All CGTX news →
CGTX Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 2.6991
Alpha: -77.24%
Correlation: 0.3564
R-Squared: 12.7%
Stock Volatility: 96.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CGTX
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $797K | #2416 of 3138 | -37.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $22K | #3703 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CGTX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
CGTX Insider Trading (Form 4)
Latest: 2026-06-22Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Ellen B Richstone | Director | Award (A) | +25,000 | — | EDGAR | |
| 2026-06-22 | Jack A. Khattar | Director | Award (A) | +25,000 | — | EDGAR | |
| 2026-06-22 | Peggy Wallace | Director | Award (A) | +25,000 | — | EDGAR | |
| 2026-06-22 | Brett P Monia | Director | Award (A) | +25,000 | — | EDGAR | |
| 2026-06-22 | BIOS Advisors GP, LLC | Director | Award (A) | +250,000 | — | EDGAR | |
| 2026-05-04 | John Brendan Doyle | Chief Financial Officer | Tax (F) | −8,567 | $1.28 | -$11.0K | EDGAR |
| 2026-04-20 | Lisa Ricciardi | CEO & President | Buy (P) | +9,175 | $1.10 | $10.1K | EDGAR |
| 2026-04-20 | John Brendan Doyle | Chief Financial Officer | Buy (P) | +10,000 | $1.13 | $11.3K | EDGAR |
| 2026-04-20 | Anthony Caggiano | Chief Medical Officer | Buy (P) | +10,000 | $1.11 | $11.1K | EDGAR |
| 2026-02-18 | Anthony Caggiano | Chief Medical Officer | Tax (F) | −4,680 | $1.12 | -$5.2K | EDGAR |
| 2026-02-18 | John Brendan Doyle | Chief Financial Officer | Tax (F) | −1,560 | $1.12 | -$1.7K | EDGAR |
| 2026-02-18 | Lisa Ricciardi | CEO & President | Tax (F) | −5,850 | $1.12 | -$6.6K | EDGAR |
| 2026-02-05 | John Brendan Doyle | Chief Financial Officer | Mixed | +173,079 | $1.03 | -$27.7K | EDGAR |
| 2026-02-05 | Anthony Caggiano | Chief Medical Officer | Mixed | +361,593 | $1.06 | -$40.6K | EDGAR |
| 2026-02-05 | Lisa Ricciardi | CEO & President | Mixed | +722,260 | $1.06 | -$82.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CGTX Insider Holdings
11 insiders · @ $0.69
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lisa Ricciardi | CEO & President | 1,754,702 | $1.22M | $215.7K | 16 | 2026-04-20 |
| 2 | Anthony Caggiano | Chief Medical Officer | 874,906 | $608.0K | $11.1K | 12 | 2026-04-20 |
| 3 | John Brendan Doyle | Chief Financial Officer | 618,942 | $430.1K | $11.3K | 12 | 2026-05-04 |
| 4 | Aaron G.L. Fletcher | Director | 475,155 | $330.2K | $2.28M | 2 | 2025-09-23 |
| 5 | Cavu Advisors, LLC | Director | 385,248 | $267.7K | $0 | 4 | 2025-06-20 |
| 6 | BIOS Fund II QP, LP | Director | 358,248 | $248.9K | $0 | 1 | 2025-06-20 |
| 7 | BIOS Advisors GP, LLC | Director | 159,527 | $110.9K | $0 | 3 | 2026-06-22 |
| 8 | Peggy Wallace | Director | 111,461 | $77.5K | $51.0K | 9 | 2026-06-22 |
| 9 | Ellen B Richstone | Director | 83,500 | $58.0K | $26.5K | 8 | 2026-06-22 |
| 10 | Brett P Monia | Director | 73,500 | $51.1K | $0 | 6 | 2026-06-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CGTX Board & Officers
As of SEC filings through Jun 22, 2026Directors 25
- Aaron G.L. Fletcher · since Oct 7, 2021
- Brett P Monia · since Oct 7, 2021
- Jack A. Khattar · since Oct 7, 2021
- Lisa Ricciardi · since Oct 7, 2021
- Peggy Wallace · since Oct 7, 2021
- Ellen B Richstone · since Nov 1, 2021
- Leslie W. Kreis · listed since Jun 2022
- BIOS Advisors GP, LLC (entity) · listed since Nov 2022
- BIOS Capital Management, LP (entity) · listed since Nov 2022
- BIOS Equity Partners III, LP (entity) · listed since Nov 2022
- BIOS Fund I QP, LP (entity) · listed since Nov 2022
- BIOS Fund I, LP (entity) · listed since Nov 2022
- BIOS Fund II NT, LP (entity) · listed since Nov 2022
- BIOS Fund II QP, LP (entity) · listed since Nov 2022
- BIOS Fund II, LP (entity) · listed since Nov 2022
- BIOS Fund III NT, LP (entity) · listed since Nov 2022
- BIOS Fund III QP, LP (entity) · listed since Nov 2022
- BIOS Fund III, LP (entity) · listed since Nov 2022
- BIOS Memory SPV I, LP (entity) · listed since Nov 2022
- BIOS Memory SPV II, LP (entity) · listed since Nov 2022
- Bios Equity Partners II, LP (entity) · listed since Nov 2022
- Bios Equity Partners, LP (entity) · listed since Nov 2022
- Cavu Advisors, LLC (entity) · listed since Nov 2022
- Cavu Management, LP (entity) · listed since Nov 2022
- BP Directors, LP (entity) · listed since Nov 2023
Officers 3
- Lisa Ricciardi · CEO & President · since Oct 7, 2021
- John Brendan Doyle · Chief Financial Officer · since May 1, 2023
- Anthony Caggiano · Chief Medical Officer · since Nov 1, 2021
10% owners 20
- Aaron G.L. Fletcher · listed since Nov 2022
- BIOS Advisors GP, LLC (entity) · since Oct 7, 2021
- BIOS Capital Management, LP (entity) · since Oct 7, 2021
- BIOS Equity Partners III, LP (entity) · since Oct 7, 2021
- BIOS Fund I QP, LP (entity) · since Oct 7, 2021
- BIOS Fund I, LP (entity) · since Oct 7, 2021
- BIOS Fund II NT, LP (entity) · since Oct 7, 2021
- BIOS Fund II QP, LP (entity) · since Oct 7, 2021
- BIOS Fund II, LP (entity) · since Oct 7, 2021
- BIOS Fund III NT, LP (entity) · since Oct 7, 2021
- BIOS Fund III QP, LP (entity) · since Oct 7, 2021
- BIOS Fund III, LP (entity) · since Oct 7, 2021
- BIOS Memory SPV I, LP (entity) · since Oct 7, 2021
- BIOS Memory SPV II, LP (entity) · since Oct 7, 2021
- BP Directors, LP (entity) · listed since Nov 2023
- Bios Equity Partners II, LP (entity) · since Oct 7, 2021
- Bios Equity Partners, LP (entity) · since Oct 7, 2021
- Cavu Advisors, LLC (entity) · since Oct 7, 2021
- Cavu Management, LP (entity) · since Oct 7, 2021
- Leslie W. Kreis · listed since Nov 2022
Changes in the last 10 years (74)
| Nov 13, 2023 | BP Directors, LP first listed as a director in an SEC filing |
| Nov 13, 2023 | BP Directors, LP first listed as a 10% owner in an SEC filing |
| Nov 8, 2023 | Bios Equity COF, LP became a director |
| Nov 8, 2023 | Bios Equity COF, LP became a 10% owner |
| Nov 8, 2023 | Bios Clinical Opportunity Fund, LP became a director |
| Nov 8, 2023 | Bios Clinical Opportunity Fund, LP became a 10% owner |
| May 1, 2023 | The company announced the departure of Andrew J. Einhorn as Interim CFO in an SEC filing |
| May 1, 2023 | John Brendan Doyle became Chief Financial Officer |
| Nov 29, 2022 | Leslie W. Kreis first listed as a 10% owner in an SEC filing |
| Nov 29, 2022 | Cavu Management, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | Cavu Advisors, LLC first listed as a director in an SEC filing |
| Nov 29, 2022 | Bios Equity Partners, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | Bios Equity Partners II, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Memory SPV II, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Memory SPV I, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund III, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund III QP, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund III NT, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund II, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund II QP, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund II NT, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund I, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Fund I QP, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Equity Partners III, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Capital Management, LP first listed as a director in an SEC filing |
| Nov 29, 2022 | BIOS Advisors GP, LLC first listed as a director in an SEC filing |
| Nov 29, 2022 | Aaron G.L. Fletcher first listed as a 10% owner in an SEC filing |
| Nov 16, 2022 | Leslie W. Kreis no longer listed as a 10% owner in SEC filings |
| Nov 16, 2022 | Cavu Management, LP no longer listed as a director in SEC filings |
| Nov 16, 2022 | Cavu Advisors, LLC no longer listed as a director in SEC filings |
| Nov 16, 2022 | Bios Equity Partners, LP no longer listed as a director in SEC filings |
| Nov 16, 2022 | BIOS Capital Management, LP no longer listed as a director in SEC filings |
| Nov 16, 2022 | BIOS Advisors GP, LLC no longer listed as a director in SEC filings |
| Nov 16, 2022 | Aaron G.L. Fletcher no longer listed as a 10% owner in SEC filings |
| Sep 29, 2022 | Golden Seeds Cognition Therapeutics LLC reported in an SEC filing no longer being a 10% owner |
| Aug 12, 2022 | Andrew J. Einhorn became Interim CFO |
| Jun 30, 2022 | Leslie W. Kreis first listed as a director in an SEC filing |
| Jun 14, 2022 | Cavu Management, LP first listed as a director in an SEC filing |
| Jun 14, 2022 | Cavu Advisors, LLC first listed as a director in an SEC filing |
| Jun 14, 2022 | Bios Equity Partners, LP first listed as a director in an SEC filing |
| Jun 14, 2022 | BIOS Capital Management, LP first listed as a director in an SEC filing |
| Jun 14, 2022 | BIOS Advisors GP, LLC first listed as a director in an SEC filing |
| Feb 1, 2022 | Aaron G.L. Fletcher first listed as a 10% owner in an SEC filing |
| Nov 1, 2021 | Ellen B Richstone became a director |
| Nov 1, 2021 | Anthony Caggiano became Chief Medical Officer |
| Oct 29, 2021 | The company announced the departure of Mark H. Breedlove from the board in an SEC filing |
| Oct 7, 2021 | Peggy Wallace became a director |
| Oct 7, 2021 | Ogden CAP Associates, LLC became a 10% owner |
| Oct 7, 2021 | Mark H. Breedlove became a director |
| Oct 7, 2021 | Lisa Ricciardi became a director |
| Oct 7, 2021 | Lisa Ricciardi became CEO & President |
| Oct 7, 2021 | Leslie W. Kreis became a 10% owner |
| Oct 7, 2021 | James Michael O'Brien became Chief Financial Officer |
| Oct 7, 2021 | Jack A. Khattar became a director |
| Oct 7, 2021 | Golden Seeds Cognition Therapeutics LLC became a 10% owner |
| Oct 7, 2021 | Cavu Management, LP became a 10% owner |
| Oct 7, 2021 | Cavu Advisors, LLC became a 10% owner |
| Oct 7, 2021 | Brett P Monia became a director |
| Oct 7, 2021 | Bios Equity Partners, LP became a 10% owner |
| Oct 7, 2021 | Bios Equity Partners II, LP became a 10% owner |
| Oct 7, 2021 | BIOS Memory SPV II, LP became a 10% owner |
| Oct 7, 2021 | BIOS Memory SPV I, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund III, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund III QP, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund III NT, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund II, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund II QP, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund II NT, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund I, LP became a 10% owner |
| Oct 7, 2021 | BIOS Fund I QP, LP became a 10% owner |
| Oct 7, 2021 | BIOS Equity Partners III, LP became a 10% owner |
| Oct 7, 2021 | BIOS Capital Management, LP became a 10% owner |
| Oct 7, 2021 | BIOS Advisors GP, LLC became a 10% owner |
| Oct 7, 2021 | Aaron G.L. Fletcher became a director |
Not reported recently (4)
- Bios Equity COF, LP · Last reported as a director in an SEC filing dated Nov 13, 2023
- Bios Clinical Opportunity Fund, LP · Last reported as a director in an SEC filing dated Nov 13, 2023
- James Michael O'Brien · Last reported as Chief Financial Officer in an SEC filing dated Mar 25, 2022
- Ogden CAP Associates, LLC · Last reported as a 10% owner in an SEC filing dated Oct 15, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
4 ETFs hold CGTX
4 shown · $3.42M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $2.3M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $886,942 | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $180,916 | $1.2B | 2026-10-23 |
| 4 | IBRN iShares Neuroscience and Healthcare ETF | iShares (BlackRock) | 0.10% | $6,111 | $6.3M | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.